https://scholars.lib.ntu.edu.tw/handle/123456789/534083
標題: | Taiwan consensus statement on the management of chronic hepatitis B | 作者: | Chien R.-N. JIA-HORNG KAO Peng C.-Y. Chen C.-H. CHUN-JEN LIU Huang Y.-H. Hu T.-H. Yang H.-I. Lu S.-N. YEN-HSUAN NI Chuang W.-L. Lee C.-M. Wu J.-C. PEI-JER CHEN Liaw Y.-F. |
公開日期: | 2019 | 出版社: | Elsevier B.V. | 卷: | 118 | 期: | 1P1 | 起(迄)頁: | 7-38 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | The experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the statement on HBV management before. However, there are more and more new data on the natural history and treatment of HBV infection in the past decade. These include new application of an old biomarker (quantitative HBsAg), clinical significance of HBV genotype and naturally occurring mutations, the role of non-invasive examination in evaluating severity of hepatic fibrosis, clinical significance of outcome calculators, new drug or new combination strategies towards more effective therapy and organ transplantation including liver and non-liver transplantation. It is time to publish the guidelines on HBV management of Taiwan. Hence, TASL have conducted an expert meeting to review, to discuss and to debate the relevant literatures, followed by draft the manuscript of HBV management guidelines and recommendations. The guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patient receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057814461&doi=10.1016%2fj.jfma.2018.11.008&partnerID=40&md5=9a6f83a13fea407fc8cd2f7a41167c8f https://scholars.lib.ntu.edu.tw/handle/123456789/534083 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.11.008 | SDG/關鍵字: | alanine aminotransferase; biological marker; entecavir; hepatitis B core antigen; hepatitis B surface antigen; hepatitis B(e) antigen; interleukin 28B; peginterferon alpha; tenofovir alafenamide; tenofovir disoproxil; virus DNA; alpha interferon; antivirus agent; entecavir; guanine; hepatitis B surface antigen; hepatitis B vaccine; antiviral resistance; Article; cancer chemotherapy; chronic hepatitis B; consensus; decompensated liver cirrhosis; disease severity; genotype; Hepatitis B virus; human; immunosuppressive treatment; liver cell carcinoma; liver cirrhosis; liver fibrosis; liver transplantation; mixed infection; non invasive procedure; nonhuman; patient monitoring; practice guideline; pregnancy; Taiwan; treatment response; analogs and derivatives; blood; chronic hepatitis B; complication; disease exacerbation; disease management; drug effect; female; Human immunodeficiency virus infection; liver cell carcinoma; liver cirrhosis; liver tumor; male; medical society; preventive health service; Taiwan; virology; virus load; Antiviral Agents; Carcinoma, Hepatocellular; Consensus; Disease Management; Disease Progression; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Immunization Programs; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Pregnancy; Societies, Medical; Taiwan; Viral Load |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。